Article

Key clinical point: Real-world study demonstrated that ixekizumab improved disease severity and symptom burden in patients with psoriatic arthritis (PsA).

Major finding: Treatment with ixekizumab led to a significant reduction in the mean overall number of symptoms at the most recent consultation vs baseline (3.4 vs 5.8), tender joint count (2.9 vs 12.3), swollen joint count (3.0 vs 10.3), pain score (2.4 vs 5.7), fatigue score (2.8 vs 5.2), and proportion of patients with severe disease (2% vs 19%; all P < .001), respectively.

Study details: This study used data from the Adelphi PsA Plus Disease Specific Programme (DSP), a cross-sectional survey which included 275 patients with PsA who were prescribed ixekizumab, of whom 55% received ixekizumab as first-line therapy.

Disclosures: The DSP is a wholly owned product of Adelphi Real World. Eli Lilly and Company was a subscriber to the DSP. Eight authors declared being employees or stockowners of Eli Lilly and Company or Adelphi Real World. Several authors declared ties with various sources, including Eli Lilly.

Source: Rohekar S, Vadhariya A, Ross S, et al. Real-world treatment patterns, clinical outcomes, and symptom burden in patients with psoriatic arthritis prescribed ixekizumab in the United States. ACR Open Rheumatol. Published online May 5, 2024. Source

Key clinical point: Real-world study demonstrated that ixekizumab improved disease severity and symptom burden in patients with psoriatic arthritis (PsA).

Major finding: Treatment with ixekizumab led to a significant reduction in the mean overall number of symptoms at the most recent consultation vs baseline (3.4 vs 5.8), tender joint count (2.9 vs 12.3), swollen joint count (3.0 vs 10.3), pain score (2.4 vs 5.7), fatigue score (2.8 vs 5.2), and proportion of patients with severe disease (2% vs 19%; all P < .001), respectively.

Study details: This study used data from the Adelphi PsA Plus Disease Specific Programme (DSP), a cross-sectional survey which included 275 patients with PsA who were prescribed ixekizumab, of whom 55% received ixekizumab as first-line therapy.

Disclosures: The DSP is a wholly owned product of Adelphi Real World. Eli Lilly and Company was a subscriber to the DSP. Eight authors declared being employees or stockowners of Eli Lilly and Company or Adelphi Real World. Several authors declared ties with various sources, including Eli Lilly.

Source: Rohekar S, Vadhariya A, Ross S, et al. Real-world treatment patterns, clinical outcomes, and symptom burden in patients with psoriatic arthritis prescribed ixekizumab in the United States. ACR Open Rheumatol. Published online May 5, 2024. Source

Key clinical point: Real-world study demonstrated that ixekizumab improved disease severity and symptom burden in patients with psoriatic arthritis (PsA).

Major finding: Treatment with ixekizumab led to a significant reduction in the mean overall number of symptoms at the most recent consultation vs baseline (3.4 vs 5.8), tender joint count (2.9 vs 12.3), swollen joint count (3.0 vs 10.3), pain score (2.4 vs 5.7), fatigue score (2.8 vs 5.2), and proportion of patients with severe disease (2% vs 19%; all P < .001), respectively.

Study details: This study used data from the Adelphi PsA Plus Disease Specific Programme (DSP), a cross-sectional survey which included 275 patients with PsA who were prescribed ixekizumab, of whom 55% received ixekizumab as first-line therapy.

Disclosures: The DSP is a wholly owned product of Adelphi Real World. Eli Lilly and Company was a subscriber to the DSP. Eight authors declared being employees or stockowners of Eli Lilly and Company or Adelphi Real World. Several authors declared ties with various sources, including Eli Lilly.

Source: Rohekar S, Vadhariya A, Ross S, et al. Real-world treatment patterns, clinical outcomes, and symptom burden in patients with psoriatic arthritis prescribed ixekizumab in the United States. ACR Open Rheumatol. Published online May 5, 2024. Source

Key clinical point: Guselkumab treatment for 4 months was effective in patients with psoriatic arthritis (PsA) who had inflammatory back pain associated with suggestive axial involvement assessed by MRI or X-ray.

Major finding: At 4 months, the Bath Ankylosing Spondylitis Disease Activity Index scores reduced significantly in patients receiving guselkumab (mean difference, −2.11 ± 0.43; P < .05), with nearly half of the patients achieving a BASDAI score ≤ 4. Similar outcomes were observed in terms of Ankylosing Spondylitis Disease Activity Scores (P = .021) and Disease Activity in PsA scores (P = .001).

Study details: Findings are from a real-life, multicenter study including 67 patients with PsA and suggestive features of axial involvement as shown by x-ray or MRI who were treated with guselkumab for ≥ 4 months.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Ruscitti P, Pantano I, Cataldi G, et al. Short-term effectiveness of guselkumab in psoriatic arthritis patients and suggestive features of axial involvement: Results from a real-life multicentre cohort. Rheumatology (Oxford). Published online April 10, 2024. Source

Key clinical point: Guselkumab treatment for 4 months was effective in patients with psoriatic arthritis (PsA) who had inflammatory back pain associated with suggestive axial involvement assessed by MRI or X-ray.

Major finding: At 4 months, the Bath Ankylosing Spondylitis Disease Activity Index scores reduced significantly in patients receiving guselkumab (mean difference, −2.11 ± 0.43; P < .05), with nearly half of the patients achieving a BASDAI score ≤ 4. Similar outcomes were observed in terms of Ankylosing Spondylitis Disease Activity Scores (P = .021) and Disease Activity in PsA scores (P = .001).

Study details: Findings are from a real-life, multicenter study including 67 patients with PsA and suggestive features of axial involvement as shown by x-ray or MRI who were treated with guselkumab for ≥ 4 months.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Ruscitti P, Pantano I, Cataldi G, et al. Short-term effectiveness of guselkumab in psoriatic arthritis patients and suggestive features of axial involvement: Results from a real-life multicentre cohort. Rheumatology (Oxford). Published online April 10, 2024. Source

Key clinical point: Guselkumab treatment for 4 months was effective in patients with psoriatic arthritis (PsA) who had inflammatory back pain associated with suggestive axial involvement assessed by MRI or X-ray.

Major finding: At 4 months, the Bath Ankylosing Spondylitis Disease Activity Index scores reduced significantly in patients receiving guselkumab (mean difference, −2.11 ± 0.43; P < .05), with nearly half of the patients achieving a BASDAI score ≤ 4. Similar outcomes were observed in terms of Ankylosing Spondylitis Disease Activity Scores (P = .021) and Disease Activity in PsA scores (P = .001).

Study details: Findings are from a real-life, multicenter study including 67 patients with PsA and suggestive features of axial involvement as shown by x-ray or MRI who were treated with guselkumab for ≥ 4 months.

Disclosures: This study did not receive any funding. The authors declared no conflict of interests.

Source: Ruscitti P, Pantano I, Cataldi G, et al. Short-term effectiveness of guselkumab in psoriatic arthritis patients and suggestive features of axial involvement: Results from a real-life multicentre cohort. Rheumatology (Oxford). Published online April 10, 2024. Source

Key clinical point: Risk factors for psoriasis developing into clinical psoriatic arthritis (PsA) include higher age, nail involvement, increased erythrocyte sedimentation rate (ESR), and elevated high-sensitivity C-reactive protein (hs-CRP) levels.

Major finding: Age ≥ 40 years (odds ratio [OR], 1.04; P < .01), nail involvement (OR, 1.17; P < .01), increased ESR (OR, 1.03; P < .05), and elevated hs-CRP levels (OR, 1.31; P < .01) increased the risk for incident PsA in patients with psoriasis. Moreover, MRI-detected enthesitis and tenosynovitis combined with these risk factors vs the risk factors alone showed better specificity (94.3% vs 69.0%) and similar sensitivity (89.0% vs 84.6%) in diagnosing PsA.

Study details: This longitudinal case-control study included 75 patients diagnosed with clinical PsA who were compared with 345 patients with psoriasis and without PsA, all of whom were aged 18-65 years.

Disclosures: This study was supported by the Beijing Municipal Science and Technology Project. The authors declared no conflict of interests.

Source: Yao A, Wang L, Qi F, et al. Risk factors and early detection of joint damage in patients with psoriasis: A case–control study. Int J Dermatol. Published online April 29, 2024. Source

Key clinical point: Risk factors for psoriasis developing into clinical psoriatic arthritis (PsA) include higher age, nail involvement, increased erythrocyte sedimentation rate (ESR), and elevated high-sensitivity C-reactive protein (hs-CRP) levels.

Major finding: Age ≥ 40 years (odds ratio [OR], 1.04; P < .01), nail involvement (OR, 1.17; P < .01), increased ESR (OR, 1.03; P < .05), and elevated hs-CRP levels (OR, 1.31; P < .01) increased the risk for incident PsA in patients with psoriasis. Moreover, MRI-detected enthesitis and tenosynovitis combined with these risk factors vs the risk factors alone showed better specificity (94.3% vs 69.0%) and similar sensitivity (89.0% vs 84.6%) in diagnosing PsA.

Study details: This longitudinal case-control study included 75 patients diagnosed with clinical PsA who were compared with 345 patients with psoriasis and without PsA, all of whom were aged 18-65 years.

Disclosures: This study was supported by the Beijing Municipal Science and Technology Project. The authors declared no conflict of interests.

Source: Yao A, Wang L, Qi F, et al. Risk factors and early detection of joint damage in patients with psoriasis: A case–control study. Int J Dermatol. Published online April 29, 2024. Source

Key clinical point: Risk factors for psoriasis developing into clinical psoriatic arthritis (PsA) include higher age, nail involvement, increased erythrocyte sedimentation rate (ESR), and elevated high-sensitivity C-reactive protein (hs-CRP) levels.

Major finding: Age ≥ 40 years (odds ratio [OR], 1.04; P < .01), nail involvement (OR, 1.17; P < .01), increased ESR (OR, 1.03; P < .05), and elevated hs-CRP levels (OR, 1.31; P < .01) increased the risk for incident PsA in patients with psoriasis. Moreover, MRI-detected enthesitis and tenosynovitis combined with these risk factors vs the risk factors alone showed better specificity (94.3% vs 69.0%) and similar sensitivity (89.0% vs 84.6%) in diagnosing PsA.

Study details: This longitudinal case-control study included 75 patients diagnosed with clinical PsA who were compared with 345 patients with psoriasis and without PsA, all of whom were aged 18-65 years.

Disclosures: This study was supported by the Beijing Municipal Science and Technology Project. The authors declared no conflict of interests.

Source: Yao A, Wang L, Qi F, et al. Risk factors and early detection of joint damage in patients with psoriasis: A case–control study. Int J Dermatol. Published online April 29, 2024. Source

Key clinical point: Patients with psoriasis who had subclinical psoriatic arthritis (PsA) based on the presence of arthralgia had a higher likelihood of developing PsA than those with only psoriasis.

Major finding: At a mean follow-up of 33 months, 80.9% of patients had subclinical PsA, with the incidence rate of new-onset PsA being 7.7 per 100 patients-years in this group and the most predominant presentation being peripheral arthritis (82.1%). The risk of developing PsA was significantly higher in patients with subclinical PsA vs psoriasis (hazard ratio, 11.7; P = .016).

Study details: This study included 384 patients with psoriasis from two European cohorts of whom 56 patients developed new-onset PsA.

Disclosures: This study did not disclose any specific funding. Six authors declared being consultants for or having other ties with various sources. The other authors declared no conflict of interests.

Source: Zabotti A, Fagni F, Gossec L, et al. Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: Exploring the subclinical psoriatic arthritis stage. RMD Open. 2024;10:e004314. Source

Key clinical point: Patients with psoriasis who had subclinical psoriatic arthritis (PsA) based on the presence of arthralgia had a higher likelihood of developing PsA than those with only psoriasis.

Major finding: At a mean follow-up of 33 months, 80.9% of patients had subclinical PsA, with the incidence rate of new-onset PsA being 7.7 per 100 patients-years in this group and the most predominant presentation being peripheral arthritis (82.1%). The risk of developing PsA was significantly higher in patients with subclinical PsA vs psoriasis (hazard ratio, 11.7; P = .016).

Study details: This study included 384 patients with psoriasis from two European cohorts of whom 56 patients developed new-onset PsA.

Disclosures: This study did not disclose any specific funding. Six authors declared being consultants for or having other ties with various sources. The other authors declared no conflict of interests.

Source: Zabotti A, Fagni F, Gossec L, et al. Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: Exploring the subclinical psoriatic arthritis stage. RMD Open. 2024;10:e004314. Source

Key clinical point: Patients with psoriasis who had subclinical psoriatic arthritis (PsA) based on the presence of arthralgia had a higher likelihood of developing PsA than those with only psoriasis.

Major finding: At a mean follow-up of 33 months, 80.9% of patients had subclinical PsA, with the incidence rate of new-onset PsA being 7.7 per 100 patients-years in this group and the most predominant presentation being peripheral arthritis (82.1%). The risk of developing PsA was significantly higher in patients with subclinical PsA vs psoriasis (hazard ratio, 11.7; P = .016).

Study details: This study included 384 patients with psoriasis from two European cohorts of whom 56 patients developed new-onset PsA.

Disclosures: This study did not disclose any specific funding. Six authors declared being consultants for or having other ties with various sources. The other authors declared no conflict of interests.

Source: Zabotti A, Fagni F, Gossec L, et al. Risk of developing psoriatic arthritis in psoriasis cohorts with arthralgia: Exploring the subclinical psoriatic arthritis stage. RMD Open. 2024;10:e004314. Source

Key clinical point: Risankizumab showed consistent long-term efficacy in patients with active psoriatic arthritis (PsA) regardless of baseline demographic, disease characteristics, and prior medication use.

Major finding: At week 24, a higher number of patients receiving risankizumab vs placebo achieved ≥ 20% improvement in the American College of Rheumatology response (ACR20; 46.3%-60.1% vs 15.5%-36.2%) despite varying demographic and disease characteristics. At week 52, similar proportions of patients who were randomized to risankizumab (48.6%-75.8%) or who switched from placebo to risankizumab (43.7%-63.9%) achieved ACR20.

Study details: This post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 trials included 1235 patients with active PsA and prior inadequate response or intolerance to conventional synthetic or biologic disease-modifying antirheumatic drugs who received risankizumab or placebo with crossover to risankizumab at week 24.

Disclosures: This study was funded by AbbVie. Four authors declared being employees of and holding stocks or stock options with AbbVie. The other authors declared having ties with AbbVie and various sources.

Source: Merola JF, Armstrong A, Khattri S, et al. Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: A post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials. J Dermatolog Treat. 2024;35:2342383. Source

Key clinical point: Risankizumab showed consistent long-term efficacy in patients with active psoriatic arthritis (PsA) regardless of baseline demographic, disease characteristics, and prior medication use.

Major finding: At week 24, a higher number of patients receiving risankizumab vs placebo achieved ≥ 20% improvement in the American College of Rheumatology response (ACR20; 46.3%-60.1% vs 15.5%-36.2%) despite varying demographic and disease characteristics. At week 52, similar proportions of patients who were randomized to risankizumab (48.6%-75.8%) or who switched from placebo to risankizumab (43.7%-63.9%) achieved ACR20.

Study details: This post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 trials included 1235 patients with active PsA and prior inadequate response or intolerance to conventional synthetic or biologic disease-modifying antirheumatic drugs who received risankizumab or placebo with crossover to risankizumab at week 24.

Disclosures: This study was funded by AbbVie. Four authors declared being employees of and holding stocks or stock options with AbbVie. The other authors declared having ties with AbbVie and various sources.

Source: Merola JF, Armstrong A, Khattri S, et al. Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: A post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials. J Dermatolog Treat. 2024;35:2342383. Source

Key clinical point: Risankizumab showed consistent long-term efficacy in patients with active psoriatic arthritis (PsA) regardless of baseline demographic, disease characteristics, and prior medication use.

Major finding: At week 24, a higher number of patients receiving risankizumab vs placebo achieved ≥ 20% improvement in the American College of Rheumatology response (ACR20; 46.3%-60.1% vs 15.5%-36.2%) despite varying demographic and disease characteristics. At week 52, similar proportions of patients who were randomized to risankizumab (48.6%-75.8%) or who switched from placebo to risankizumab (43.7%-63.9%) achieved ACR20.

Study details: This post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 trials included 1235 patients with active PsA and prior inadequate response or intolerance to conventional synthetic or biologic disease-modifying antirheumatic drugs who received risankizumab or placebo with crossover to risankizumab at week 24.

Disclosures: This study was funded by AbbVie. Four authors declared being employees of and holding stocks or stock options with AbbVie. The other authors declared having ties with AbbVie and various sources.

Source: Merola JF, Armstrong A, Khattri S, et al. Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: A post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials. J Dermatolog Treat. 2024;35:2342383. Source

Key clinical point: Secukinumab demonstrated rapid improvements in clinical outcomes and showed a consistent safety profile in challenging-to-treat patients with psoriatic arthritis (PsA) who had high BMI and showed higher tender and swollen joints despite previous treatment.

Major finding: At week 16, patients receiving secukinumab 300 mg and 150 mg with loading dose vs placebo had a higher rate of achieving the American College of Rheumatology 20 response (59.7% and 43.4%, respectively, vs 15.6%; both P < .0001) and the Psoriasis Area and Severity Index 90 response (47.1% and 22.2%, respectively, vs 5.3%; both P < .05).

Study details: This subgroup analysis of four phase 3 FUTURE studies included 279 patients with challenging-to-treat PsA from the United States who received secukinumab or placebo and had undergone prior treatment with nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, or corticosteroids.

Disclosures: This study was supported by Novartis Pharmaceuticals Corporation, United States. Luminita Pricop declared being an employee and stockholder of Novartis. The other authors declared receiving research grants from or having other ties with Novartis or others.

Source: Kivitz AJ, Kremer JM, Legerton CW 3rd, Pricop L, Singhal A. Efficacy and safety of secukinumab in US patients with psoriatic arthritis: A subgroup analysis of the phase 3 FUTURE studies. Rheumatol Ther. Published online April 16, 2024. Source

Key clinical point: Secukinumab demonstrated rapid improvements in clinical outcomes and showed a consistent safety profile in challenging-to-treat patients with psoriatic arthritis (PsA) who had high BMI and showed higher tender and swollen joints despite previous treatment.

Major finding: At week 16, patients receiving secukinumab 300 mg and 150 mg with loading dose vs placebo had a higher rate of achieving the American College of Rheumatology 20 response (59.7% and 43.4%, respectively, vs 15.6%; both P < .0001) and the Psoriasis Area and Severity Index 90 response (47.1% and 22.2%, respectively, vs 5.3%; both P < .05).

Study details: This subgroup analysis of four phase 3 FUTURE studies included 279 patients with challenging-to-treat PsA from the United States who received secukinumab or placebo and had undergone prior treatment with nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, or corticosteroids.

Disclosures: This study was supported by Novartis Pharmaceuticals Corporation, United States. Luminita Pricop declared being an employee and stockholder of Novartis. The other authors declared receiving research grants from or having other ties with Novartis or others.

Source: Kivitz AJ, Kremer JM, Legerton CW 3rd, Pricop L, Singhal A. Efficacy and safety of secukinumab in US patients with psoriatic arthritis: A subgroup analysis of the phase 3 FUTURE studies. Rheumatol Ther. Published online April 16, 2024. Source

Key clinical point: Secukinumab demonstrated rapid improvements in clinical outcomes and showed a consistent safety profile in challenging-to-treat patients with psoriatic arthritis (PsA) who had high BMI and showed higher tender and swollen joints despite previous treatment.

Major finding: At week 16, patients receiving secukinumab 300 mg and 150 mg with loading dose vs placebo had a higher rate of achieving the American College of Rheumatology 20 response (59.7% and 43.4%, respectively, vs 15.6%; both P < .0001) and the Psoriasis Area and Severity Index 90 response (47.1% and 22.2%, respectively, vs 5.3%; both P < .05).

Study details: This subgroup analysis of four phase 3 FUTURE studies included 279 patients with challenging-to-treat PsA from the United States who received secukinumab or placebo and had undergone prior treatment with nonsteroidal anti-inflammatory drugs, disease-modifying antirheumatic drugs, or corticosteroids.

Disclosures: This study was supported by Novartis Pharmaceuticals Corporation, United States. Luminita Pricop declared being an employee and stockholder of Novartis. The other authors declared receiving research grants from or having other ties with Novartis or others.

Source: Kivitz AJ, Kremer JM, Legerton CW 3rd, Pricop L, Singhal A. Efficacy and safety of secukinumab in US patients with psoriatic arthritis: A subgroup analysis of the phase 3 FUTURE studies. Rheumatol Ther. Published online April 16, 2024. Source

Key clinical point: Treatment with 15 mg or 30 mg upadacitinib demonstrated rapid and durable improvements in symptoms and quality of life in adults with moderate to severe atopic dermatitis (AD), based on a treat-to-target approach.

Major finding: Overall, >80%, >78%, and ≥87% of patients achieved the 3-month initial acceptable target, whereas ≥53%, >61%, and >73% of patients achieved the 6-month optimal target goal with 15 mg or 30 mg upadacitinib vs placebo at weeks 2, 16, and 52, respectively. The proportion of patients achieving a higher number of individual target criteria increased over time for both 3- and 6-month target goals.

Study details: This treat-to-target analysis of Measure Up 1 and Measure Up 2 phase 3 studies included 1282 adults with moderate to severe AD who were randomly assigned to receive 15 mg upadacitinib (n = 428), 30 mg upadacitinib (n = 424), or placebo (n = 430).

Disclosures: This study was funded by AbbVie. Five authors declared being employees of AbbVie or holding AbbVie stock, stock options, or patents. Several authors declared having ties with various sources, including AbbVie.

Source: Kwatra SG, de Bruin-Weller M, Silverberg JI, et al. Targeted combined endpoint improvement in patient and disease domains in atopic dermatitis: A treat-to-target analysis of adults with moderate-to-severe atopic dermatitis treated with upadacitinib. Acta Derm Venereol. 2024;104:adv18452 (May 6). doi: 10.2340/actadv.v104.18452 Source

Key clinical point: Treatment with 15 mg or 30 mg upadacitinib demonstrated rapid and durable improvements in symptoms and quality of life in adults with moderate to severe atopic dermatitis (AD), based on a treat-to-target approach.

Major finding: Overall, >80%, >78%, and ≥87% of patients achieved the 3-month initial acceptable target, whereas ≥53%, >61%, and >73% of patients achieved the 6-month optimal target goal with 15 mg or 30 mg upadacitinib vs placebo at weeks 2, 16, and 52, respectively. The proportion of patients achieving a higher number of individual target criteria increased over time for both 3- and 6-month target goals.

Study details: This treat-to-target analysis of Measure Up 1 and Measure Up 2 phase 3 studies included 1282 adults with moderate to severe AD who were randomly assigned to receive 15 mg upadacitinib (n = 428), 30 mg upadacitinib (n = 424), or placebo (n = 430).

Disclosures: This study was funded by AbbVie. Five authors declared being employees of AbbVie or holding AbbVie stock, stock options, or patents. Several authors declared having ties with various sources, including AbbVie.

Source: Kwatra SG, de Bruin-Weller M, Silverberg JI, et al. Targeted combined endpoint improvement in patient and disease domains in atopic dermatitis: A treat-to-target analysis of adults with moderate-to-severe atopic dermatitis treated with upadacitinib. Acta Derm Venereol. 2024;104:adv18452 (May 6). doi: 10.2340/actadv.v104.18452 Source

Key clinical point: Treatment with 15 mg or 30 mg upadacitinib demonstrated rapid and durable improvements in symptoms and quality of life in adults with moderate to severe atopic dermatitis (AD), based on a treat-to-target approach.

Major finding: Overall, >80%, >78%, and ≥87% of patients achieved the 3-month initial acceptable target, whereas ≥53%, >61%, and >73% of patients achieved the 6-month optimal target goal with 15 mg or 30 mg upadacitinib vs placebo at weeks 2, 16, and 52, respectively. The proportion of patients achieving a higher number of individual target criteria increased over time for both 3- and 6-month target goals.

Study details: This treat-to-target analysis of Measure Up 1 and Measure Up 2 phase 3 studies included 1282 adults with moderate to severe AD who were randomly assigned to receive 15 mg upadacitinib (n = 428), 30 mg upadacitinib (n = 424), or placebo (n = 430).

Disclosures: This study was funded by AbbVie. Five authors declared being employees of AbbVie or holding AbbVie stock, stock options, or patents. Several authors declared having ties with various sources, including AbbVie.

Source: Kwatra SG, de Bruin-Weller M, Silverberg JI, et al. Targeted combined endpoint improvement in patient and disease domains in atopic dermatitis: A treat-to-target analysis of adults with moderate-to-severe atopic dermatitis treated with upadacitinib. Acta Derm Venereol. 2024;104:adv18452 (May 6). doi: 10.2340/actadv.v104.18452 Source

Key clinical point: Dupilumab treatment was well-tolerated and demonstrated improved clinical and molecular responses in pediatric patients with moderate to severe atopic dermatitis (AD).

Major finding: Dupilumab significantly reduced Eczema Area and Severity Index, SCORing Atopic Dermatitis index, and Investigator’s Global Assessment scores at 3 and 6 months (all P < .05), along with significant reduction in AD-associated stratum corneum biomarker levels at 3 months (P < .01). Dupilumab showed good tolerability, with adverse events reported in only four patients.

Study details: This study included 314 pediatric patients with moderate to severe AD from the German TREATkids registry, of whom 87 received dupilumab.

Disclosures: TREATkids is the child and adolescent section of the TREATgermany registry, which is supported by AbbVie Deutschland GmbH & Co. KG, Almirall Hermal GmbH, Galderma S.A., LEO Pharma GmbH, Lilly Deutschland GmbH, Pfizer Inc., and Sanofi. Several authors declared receiving research grants, lecture, or consultancy fees from or having other ties with various sources, including the supporters of TREATgermany.

Source: Stölzl D, Sander N, Siegels D, et al, and the TREATgermany study group. Clinical and molecular response to dupilumab treatment in pediatric atopic dermatitis: Results of the German TREATkids registry. Allergy. 2024 (May 7). doi: 0.1111/all.16147 Source

Key clinical point: Dupilumab treatment was well-tolerated and demonstrated improved clinical and molecular responses in pediatric patients with moderate to severe atopic dermatitis (AD).

Major finding: Dupilumab significantly reduced Eczema Area and Severity Index, SCORing Atopic Dermatitis index, and Investigator’s Global Assessment scores at 3 and 6 months (all P < .05), along with significant reduction in AD-associated stratum corneum biomarker levels at 3 months (P < .01). Dupilumab showed good tolerability, with adverse events reported in only four patients.

Study details: This study included 314 pediatric patients with moderate to severe AD from the German TREATkids registry, of whom 87 received dupilumab.

Disclosures: TREATkids is the child and adolescent section of the TREATgermany registry, which is supported by AbbVie Deutschland GmbH & Co. KG, Almirall Hermal GmbH, Galderma S.A., LEO Pharma GmbH, Lilly Deutschland GmbH, Pfizer Inc., and Sanofi. Several authors declared receiving research grants, lecture, or consultancy fees from or having other ties with various sources, including the supporters of TREATgermany.

Source: Stölzl D, Sander N, Siegels D, et al, and the TREATgermany study group. Clinical and molecular response to dupilumab treatment in pediatric atopic dermatitis: Results of the German TREATkids registry. Allergy. 2024 (May 7). doi: 0.1111/all.16147 Source

Key clinical point: Dupilumab treatment was well-tolerated and demonstrated improved clinical and molecular responses in pediatric patients with moderate to severe atopic dermatitis (AD).

Major finding: Dupilumab significantly reduced Eczema Area and Severity Index, SCORing Atopic Dermatitis index, and Investigator’s Global Assessment scores at 3 and 6 months (all P < .05), along with significant reduction in AD-associated stratum corneum biomarker levels at 3 months (P < .01). Dupilumab showed good tolerability, with adverse events reported in only four patients.

Study details: This study included 314 pediatric patients with moderate to severe AD from the German TREATkids registry, of whom 87 received dupilumab.

Disclosures: TREATkids is the child and adolescent section of the TREATgermany registry, which is supported by AbbVie Deutschland GmbH & Co. KG, Almirall Hermal GmbH, Galderma S.A., LEO Pharma GmbH, Lilly Deutschland GmbH, Pfizer Inc., and Sanofi. Several authors declared receiving research grants, lecture, or consultancy fees from or having other ties with various sources, including the supporters of TREATgermany.

Source: Stölzl D, Sander N, Siegels D, et al, and the TREATgermany study group. Clinical and molecular response to dupilumab treatment in pediatric atopic dermatitis: Results of the German TREATkids registry. Allergy. 2024 (May 7). doi: 0.1111/all.16147 Source

Key clinical point: Lebrikizumab monotherapy rapidly and consistently reduced atopic dermatitis (AD) extent and severity in patients with moderate to severe AD across all Eczema Area and Severity Index (EASI) clinical signs and body regions.

Major finding: At week 16, lebrikizumab vs placebo led to greater improvements in EASI scores and clinical signs (both P < .001) across all body regions in ADvocate1 and ADvocate2, with improvements observed as early as week 2 for all signs except erythema on head/neck (P < .05) and lower extremity erythema, edema/papulation, and lichenification (all P < .001), which improved significantly only by week 4 in ADvocate2.

Study details: This post hoc analysis of ADvocate1 (n = 424) and ADvocate2 (n = 427) included adolescent and adult patients with moderate to severe AD who were randomly assigned to receive 250 mg lebrikizumab biweekly or placebo.

Disclosures: This study was funded by Dermira, Inc., a wholly owned subsidiary of Eli Lilly and Company. Several authors declared having various ties with Dermira, Eli Lilly, and others. Five authors declared being employees or stockholders of Eli Lilly.

Source: Simpson EL, de Bruin-Weller M, Hong HC, et al. Lebrikizumab provides rapid clinical responses across all Eczema Area and Severity Index body regions and clinical signs in adolescents and adults with moderate-to-severe atopic dermatitis. Dermatol Ther (Heidelb). 2024 (May 3). doi: 10.1007/s13555-024-01158-4 Source

Key clinical point: Lebrikizumab monotherapy rapidly and consistently reduced atopic dermatitis (AD) extent and severity in patients with moderate to severe AD across all Eczema Area and Severity Index (EASI) clinical signs and body regions.

Major finding: At week 16, lebrikizumab vs placebo led to greater improvements in EASI scores and clinical signs (both P < .001) across all body regions in ADvocate1 and ADvocate2, with improvements observed as early as week 2 for all signs except erythema on head/neck (P < .05) and lower extremity erythema, edema/papulation, and lichenification (all P < .001), which improved significantly only by week 4 in ADvocate2.

Study details: This post hoc analysis of ADvocate1 (n = 424) and ADvocate2 (n = 427) included adolescent and adult patients with moderate to severe AD who were randomly assigned to receive 250 mg lebrikizumab biweekly or placebo.

Disclosures: This study was funded by Dermira, Inc., a wholly owned subsidiary of Eli Lilly and Company. Several authors declared having various ties with Dermira, Eli Lilly, and others. Five authors declared being employees or stockholders of Eli Lilly.

Source: Simpson EL, de Bruin-Weller M, Hong HC, et al. Lebrikizumab provides rapid clinical responses across all Eczema Area and Severity Index body regions and clinical signs in adolescents and adults with moderate-to-severe atopic dermatitis. Dermatol Ther (Heidelb). 2024 (May 3). doi: 10.1007/s13555-024-01158-4 Source

Key clinical point: Lebrikizumab monotherapy rapidly and consistently reduced atopic dermatitis (AD) extent and severity in patients with moderate to severe AD across all Eczema Area and Severity Index (EASI) clinical signs and body regions.

Major finding: At week 16, lebrikizumab vs placebo led to greater improvements in EASI scores and clinical signs (both P < .001) across all body regions in ADvocate1 and ADvocate2, with improvements observed as early as week 2 for all signs except erythema on head/neck (P < .05) and lower extremity erythema, edema/papulation, and lichenification (all P < .001), which improved significantly only by week 4 in ADvocate2.

Study details: This post hoc analysis of ADvocate1 (n = 424) and ADvocate2 (n = 427) included adolescent and adult patients with moderate to severe AD who were randomly assigned to receive 250 mg lebrikizumab biweekly or placebo.

Disclosures: This study was funded by Dermira, Inc., a wholly owned subsidiary of Eli Lilly and Company. Several authors declared having various ties with Dermira, Eli Lilly, and others. Five authors declared being employees or stockholders of Eli Lilly.

Source: Simpson EL, de Bruin-Weller M, Hong HC, et al. Lebrikizumab provides rapid clinical responses across all Eczema Area and Severity Index body regions and clinical signs in adolescents and adults with moderate-to-severe atopic dermatitis. Dermatol Ther (Heidelb). 2024 (May 3). doi: 10.1007/s13555-024-01158-4 Source

Key clinical point: A causal relationship was observed between genetically related atopic dermatitis (AD) and brain cancer, delineating AD as a potential risk factor for brain cancer.

Major finding: The presence of AD led to an increased risk for brain cancer (odds ratio 1.0005; P = .0096); however, no significant causal association was observed on conducting reverse Mendelian randomization analysis.

Study details: This cohort study analyzed the data on AD-associated single nucleotide polymorphisms of patients with AD (n = 15,208) and control individuals without AD (n = 367,046) from the FinnGen database (10^th release) and the summary data of patients with brain cancer (n = 606) and control individuals without cancer (n = 372,016) from the IEU Open GWAS database.

Disclosures: This study did not disclose any funding source. The authors declared no conflicts of interest.

Source: Xin Y, Yuan T, Wang J. The causal relationship between atopic dermatitis and brain cancer: A bidirectional Mendelian randomization study. Skin Res Technol. 2024;30(4):e13715. doi: 10.1111/srt.13715 Source

Key clinical point: A causal relationship was observed between genetically related atopic dermatitis (AD) and brain cancer, delineating AD as a potential risk factor for brain cancer.

Major finding: The presence of AD led to an increased risk for brain cancer (odds ratio 1.0005; P = .0096); however, no significant causal association was observed on conducting reverse Mendelian randomization analysis.

Study details: This cohort study analyzed the data on AD-associated single nucleotide polymorphisms of patients with AD (n = 15,208) and control individuals without AD (n = 367,046) from the FinnGen database (10^th release) and the summary data of patients with brain cancer (n = 606) and control individuals without cancer (n = 372,016) from the IEU Open GWAS database.

Disclosures: This study did not disclose any funding source. The authors declared no conflicts of interest.

Source: Xin Y, Yuan T, Wang J. The causal relationship between atopic dermatitis and brain cancer: A bidirectional Mendelian randomization study. Skin Res Technol. 2024;30(4):e13715. doi: 10.1111/srt.13715 Source

Key clinical point: A causal relationship was observed between genetically related atopic dermatitis (AD) and brain cancer, delineating AD as a potential risk factor for brain cancer.

Major finding: The presence of AD led to an increased risk for brain cancer (odds ratio 1.0005; P = .0096); however, no significant causal association was observed on conducting reverse Mendelian randomization analysis.

Study details: This cohort study analyzed the data on AD-associated single nucleotide polymorphisms of patients with AD (n = 15,208) and control individuals without AD (n = 367,046) from the FinnGen database (10^th release) and the summary data of patients with brain cancer (n = 606) and control individuals without cancer (n = 372,016) from the IEU Open GWAS database.

Disclosures: This study did not disclose any funding source. The authors declared no conflicts of interest.

Source: Xin Y, Yuan T, Wang J. The causal relationship between atopic dermatitis and brain cancer: A bidirectional Mendelian randomization study. Skin Res Technol. 2024;30(4):e13715. doi: 10.1111/srt.13715 Source